| Transforming Growth Factor-Beta in Cancer Therapy, Volume II: Cancer Treatment and Therapy Contributor(s): Jakowlew, Sonia B. (Editor), Heldin, C. -H (Foreword by) |
|
 |
ISBN: 1617377368 ISBN-13: 9781617377365 Publisher: Humana OUR PRICE: $265.99 Product Type: Paperback - Other Formats Published: November 2010 |
| Additional Information |
| BISAC Categories: - Medical | Oncology - General - Medical | Pharmacology - Science | Life Sciences - Cell Biology |
| Dewey: 571.6 |
| Series: Cancer Drug Discovery & Development |
| Physical Information: 1.62" H x 7" W x 10" (3.05 lbs) 786 pages |
| Descriptions, Reviews, Etc. |
| Publisher Description: Transforming Growth Factor-B in Cancer Therapy, Volume II: Cancer Treatment and Therapy The chapters in this volume confer an abundance of knowledge about the current state ofour understanding oftransforming growth factor-B (TGF-B) in cancer treatment and therapy. Unlike several more traditional positive polypeptide growth factors that stim- ulate cellular proliferation, the prototypical TGF-B is now known to inhibit the growth of most normal cell types, including those of epithelial and mesenchymal origin. However, there are examplesofcell types that can be stimulated by TGF-B under certain conditions. TGF-B also induces the accumulation of matrix molecules by stimulating their synthesis as well as inhibiting their degradation. Moreover, TGF-B induces apoptosis of certain cell types, thereby restricting their proliferation. OveractivityofTGF- has been linked to several diseases. For instance, the effect ofTGF- on matrix accumulation contributes to fibrotic conditions, like glomerulonephritis, lung fibrosis and liver cirrhosis (1). TGF- has a very complicated role in cancer that is only beginning to be understood. |